A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation

For advanced or metastatic non-small cell lung cancer (NSCLC) with actionable gene mutations, first-line targeted therapy significantly prolongs survival compared to chemotherapy and immunotherapy. Perioperative targeted therapy has achieved significant improvement in early- and locally advanced-sta...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Wenying Peng, Susu Qu, Lijuan Cai, Runxiang Yang, Mengyuan Dong, Xiang Li, Fengming Ran, Chunxiang Luo
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2025-12-01
Цуврал:	Frontiers in Medicine
Нөхцлүүд:	BRAF V600E mutation dabrafenib trametinib NSCLC neoadjuvant therapy
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1664182/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!